Targeting Glucose Transporters for Breast Cancer Therapy: The Effect of Natural and Synthetic Compounds
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Reprogramming of cellular energy metabolism is widely accepted to be a cancer hallmark. The deviant energetic metabolism of cancer cells-known as the Warburg effect-consists in much higher rates of glucose uptake and glycolytic oxidation coupled with the production of lactic acid, even in the presence of oxygen. Consequently, cancer cells have higher glucose needs and thus display a higher sensitivity to glucose deprivation-induced death than normal cells. So, inhibitors of glucose uptake are potential therapeutic targets in cancer. Breast cancer is the most commonly diagnosed cancer and a leading cause of cancer death in women worldwide. Overexpression of facilitative glucose transporters (GLUT), mainly GLUT1, in breast cancer cells is firmly established, and the consequences of GLUT inhibition and/or knockout are under investigation. Herein we review the compounds, both of natural and synthetic origin, found to interfere with uptake of glucose by breast cancer cells, and the consequences of interference with that mechanism on breast cancer cell biology. We will also present data where the interaction with GLUT is exploited in order to increase the efficiency or selectivity of anticancer agents, in breast cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“Further, another p53 activator, nutlin3a [96], also caused repression of GLUT1 mRNA expression.”
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Metformin was associated with reduced risk of developing cancer in diabetic patients in 2005 [70].”
BackgroundInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma
Pavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A. K., Frank, P. G., Casimiro, M. C., Wang, C., Fortina, P., Addya, S., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10238 · Cited by 1,391
The SLC2 (GLUT) family of membrane transporters
Mueckler, M., & Thorens, B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.001 · Cited by 1,328
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer
Macheda, M. L., Rogers, S., & Best, J. D. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20166 · Cited by 1,229
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971 · cited 3×
“Indeed, many compounds targeting energy metabolism are currently in trial or approved as therapeutic agents for cancer [48,49].”
BackgroundGlucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K. V., Markowitz, S., Zhou, S., et al. (2009) · Science · doi:10.1126/science.1174229 · Cited by 914
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides
Birsoy, K., Possemato, R., Lorbeer, F. K., Bayraktar, E. C., Thiru, P., Yucel, B., Wang, T., Chen, W. W., Clish, C. B., & Sabatini, D. M. (2014) · Nature · doi:10.1038/nature13110 · Cited by 710 · cited 1×
“Moreover, restoration of GLUT1 expression attenuated the phenformin‐sensitivity in the corresponding cancer cells [76].”
BackgroundThe role of polyphenols in modern nutrition
Williamson, G. (2017) · Nutrition Bulletin · doi:10.1111/nbu.12278 · Cited by 551
Raez, L. E., Papadopoulos, K., Ricart, A. D., Chiorean, E. G., DiPaola, R. S., Stein, M. N., Rocha Lima, C. M., Schlesselman, J. J., Tolba, K., Langmuir, V. K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2045-1 · Cited by 543
Choosing between glycolysis and oxidative phosphorylation: a tumor’s dilemma?
Jose, C., Bellance, N., & Rossignol, R. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.10.012 · Cited by 518
Glucose transporters: expression, regulation and cancer
MEDINA, R. A., & OWEN, G. I. (2002) · Biological Research · doi:10.4067/s0716-97602002000100004 · Cited by 472
Tumour-associated mutant p53 drives the Warburg effect
Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434 · cited 2×
“GLUT1 shRNA transfection SK‐BR3, MDA‐ MB‐468 glucose uptake and lactate production ‐ [66]”
BackgroundGlucose Conjugation for the Specific Targeting and Treatment of Cancer
Calvaresi, E. C., & Hergenrother, P. J. (2013) · Chemical Science · doi:10.1039/c3sc22205e · Cited by 398
Metabolic positron emission tomography imaging in cancer detection and therapy response
Zhu, A., Lee, D., & Shim, H. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.11.012 · Cited by 368 · cited 1×
“Importantly, the sensitivity of this technique varies depending on the type of cancer, and this heterogeneity has been particularly associated with GLUT1 or GLUT3 tumor expression [23,47].”
BackgroundDeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343 · cited 1×
“Palbociclib, an orally‐available inhibitor of CDK4 and CDK6, represents the most widely studied compound among cell cycle inhibitors [86].”
BackgroundA phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
Flaig, T. W., Gustafson, D. L., Su, L.-J., Zirrolli, J. A., Crighton, F., Harrison, G. S., Pierson, A. S., Agarwal, R., & Glodé, L. M. (2007) · Investigational New Drugs · doi:10.1007/s10637-006-9019-2 · Cited by 315
Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876
Siebeneicher, H., Cleve, A., Rehwinkel, H., Neuhaus, R., Heisler, I., Müller, T., Bauser, M., & Buchmann, B. (2016) · ChemMedChem · doi:10.1002/cmdc.201600276 · Cited by 294
Current status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Sun, K., Tang, S., Hou, Y., Xi, L., Chen, Y., Yin, J., Peng, M., Zhao, M., Cui, X., & Liu, M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.025 · Cited by 138
Targeting the Delivery of Glycan-Based Paclitaxel Prodrugs to Cancer Cells via Glucose Transporters
Lin, Y.-S., Tungpradit, R., Sinchaikul, S., An, F.-M., Liu, D.-Z., Phutrakul, S., & Chen, S.-T. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8006257 · Cited by 120
Targeted Cancer Therapy with a 2-Deoxyglucose-Based Adriamycin Complex
Cao, J., Cui, S., Li, S., Du, C., Tian, J., Wan, S., Qian, Z., Gu, Y., Chen, W. R., & Wang, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2072 · Cited by 84
Glycolysis inhibitors for anticancer therapy: A review of recent patents
Sheng, H., & Tang, W. (2016) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892811666160415160104 · Cited by 71
Zheng, X., Resnick, R. J., & Shalloway, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23321 · Cited by 60 · cited 1×
“Transforming (sarcoma-inducing) Gene of Rous Sarcoma Virus (Src) activation appears to be a key signaling event driving ER- and TamR breast cancer progression and thus, targeting Src may prevent ERbreast cancer [91].”
Background
Cited by
The mechanism of Warburg effect-induced chemoresistance in cancer
Liu, C., Jin, Y., & Fan, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698023 · Cited by 177
The crosstalk between HIFs and mitochondrial dysfunctions in cancer development
Bao, X., Zhang, J., Huang, G., Yan, J., Xu, C., Dou, Z., Sun, C., & Zhang, H. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03505-1 · Cited by 152
Pei, Y., Lv, S., Shi, Y., Jia, J., Ma, M., Han, H., Zhang, R., Tan, J., & Zhang, X. (2023) · Autophagy · doi:10.1080/15548627.2022.2114271 · Cited by 39
In situ metabolic Characterisation of Breast Cancer and its Potential Impact on Therapy
Petővári, G., Dankó, T., Tőkés, A.-M., Vetlényi, E., Krencz, I., Raffay, R., Hajdu, M., Sztankovics, D., Németh, K., Vellai-Takács, K., et al. (2020) · Cancers · doi:10.3390/cancers12092492 · Cited by 16
“This underlines the potential importance of other glucose transporters and the glycolysis inhibitor sensitivity of breast cancer cells in vitro [28].”
Background
Metadata
- Authors
- Barbosa, A. M., & Martel, F.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-01-08
- Volume
- 12
- Issue
- 1
- Pages
- 154
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3000120095
- Cited by
- 135
- References
- 26
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.